Berchuck A - Search Results

1

High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.

Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharoah PDP, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL; Ovarian Cancer Association Consortium. Brieger KK, et al. Among authors: berchuck a. Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):443-452. doi: 10.1158/1055-9965.EPI-21-0977. Epub 2021 Nov 17. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 34789471 Free PMC article.

2

Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery.

Rodriguez GC, Soper JT, Berchuck A, Oleson J, Dodge R, Montana G, Clarke-Pearson DL. Rodriguez GC, et al. Among authors: berchuck a. J Clin Oncol. 1992 Oct;10(10):1553-60. doi: 10.1200/JCO.1992.10.10.1553. J Clin Oncol. 1992. PMID: 1383433

3

Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.

Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC Jr. Olt G, et al. Among authors: berchuck a. Cancer. 1992 Oct 15;70(8):2137-42. doi: 10.1002/1097-0142(19921015)70:8<2137::aid-cncr2820700821>3.0.co;2-w. Cancer. 1992. PMID: 1394043

4

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, et al. Berchuck A, et al. Cancer Res. 1990 Jul 1;50(13):4087-91. Cancer Res. 1990. PMID: 1972347

5

Overexpression and mutation of p53 in epithelial ovarian cancer.

Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC Jr, Berchuck A. Marks JR, et al. Among authors: berchuck a. Cancer Res. 1991 Jun 1;51(11):2979-84. Cancer Res. 1991. PMID: 2032235

6

Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.

Schildkraut JM, Collins NK, Dent GA, Tucker JA, Barrett JC, Berchuck A, Boyd J. Schildkraut JM, et al. Among authors: berchuck a. Am J Obstet Gynecol. 1995 Mar;172(3):908-13. doi: 10.1016/0002-9378(95)90020-9. Am J Obstet Gynecol. 1995. PMID: 7892884

7

Role of BRCA1 mutation screening in the management of familial ovarian cancer.

Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Berchuck A, et al. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. doi: 10.1053/ob.1996.v175.a74288. Am J Obstet Gynecol. 1996. PMID: 8828444 Review.

8

Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.

Schildkraut JM, Bastos E, Berchuck A. Schildkraut JM, et al. Among authors: berchuck a. J Natl Cancer Inst. 1997 Jul 2;89(13):932-8. doi: 10.1093/jnci/89.13.932. J Natl Cancer Inst. 1997. PMID: 9214672

9

Oral contraceptive pills. Prevention of ovarian cancer and other benefits.

Berchuck A, Schildkraut J. Berchuck A, et al. N C Med J. 1997 Nov-Dec;58(6):404-7; discussion 408. N C Med J. 1997. PMID: 9392951 Review.

10

Managing hereditary ovarian cancer risk.

Berchuck A, Schildkraut JM, Marks JR, Futreal PA. Berchuck A, et al. Cancer. 1999 Dec 1;86(11 Suppl):2517-24. doi: 10.1002/(sici)1097-0142(19991201)86:11+<2517::aid-cncr8>3.0.co;2-b. Cancer. 1999. PMID: 10630177 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

632 results

Search Page